Therefore, the differences in the efficacy and safety of PD-1 inhibitor or PD-L1 inhibitor plus chemotherapy as first-line treatment in ES-SCLC patients remain unelucidated. This evidence concerns the gene PDCD1 and small cell lung carcinoma.